Tech Company Financing Transactions
Glycomine Funding Round
On 8/8/2019, Glycomine raised $33 million in Series B financing from Novo Ventures, Asahi Kasei and Chiesi Ventures.
Transaction Overview
Company Name
Announced On
8/8/2019
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors
Novo Ventures (Lead Investor)
Chiesi Ventures (Giacomo Chiesi)
Sanderling Ventures (Peter McWilliams)
Proceeds Purpose
The company intends to use the funds to advance its substrate replacement therapy for PMM2-CDG (CDG-1a), the most prevalent form in the spectrum of congenital diseases of glycosylation (CDG), into early stage clinical studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
733 Industrial Rd.
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Website
Email Address
Overview
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter McWilliams
Chief Medical Officer
Horacio Plotkin
Vice President
Geoffrey Hird
VP - Regulatory Affairs
Lisa Koch-Hulle
Browse more venture capital transactions:
Prev: 8/8/2019: Sunverge Energy venture capital transaction
Next: 8/9/2019: Pathstream venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs